Trials / Completed
CompletedNCT04686994
Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects
A Randomized, Double-Blind, Placebo-Controlled Phase Ib Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics (Biomarkers) of ASC41 Tables in Overweight and Obese Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Gannex Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 59 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese subjects who have elevated LDL-C .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASC 41 | Oral tablets |
| DRUG | ASC 41 Placebo | Oral tablets |
Timeline
- Start date
- 2020-12-22
- Primary completion
- 2021-01-19
- Completion
- 2021-02-07
- First posted
- 2020-12-29
- Last updated
- 2024-09-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04686994. Inclusion in this directory is not an endorsement.